#Mexico #Mexico City #pharmaceuticals #Debt Refinancing #Genomma Lab

Genomma Lab Internacional Announces Long-Term Debt Refinancing Transaction

Genomma Lab Internacional, a prominent player in the pharmaceuticals and personal care sector in Mexico, has taken a significant step towards enhancing its financial structure. Recently, the company unveiled its plans to enter into a long-term credit facility aimed at refinancing its current financial liabilities. This strategic move is expected to bolster its operational efficiency and support its growth ambitions across Mexico and Latin America.

During the refinancing process, Genomma Lab successfully secured a loan amounting to MXN 1.5 billion, characterized as an amortizing term loan with a 10-year maturity. The restructuring of their financial obligations aims to replace existing liabilities with terms that are more favorable to the company's financial health. As of now, half of the secured amount has already been utilized to retire previous debts, while the remaining funds are anticipated to be accessed during the third quarter, completing the refinancing process.

Antonio Zamora Galland, the CFO of Genomma Lab, expressed gratitude towards BANCOMEXT for their trust and support in this venture. He highlighted the company's commitment to expanding the availability of affordable over-the-counter medicines and personal care products. This refinancing is not merely a structural improvement; it marks a pivotal moment in Genomma Lab's pursuit of optimizing its debt maturity profile, enhancing the average duration of its financial commitments, and ultimately improving returns on invested capital.

The financing initiative serves a dual purpose: it not only solidifies Genomma Lab’s manufacturing capabilities but also reinforces its status as a capable exporter with robust foreign exchange generation. Such financial maneuvers are crucial as the company navigates through a competitive pharmaceutical landscape, which continues to evolve at a rapid pace.

About Genomma Lab Internacional

Genomma Lab Internacional is renowned as one of Latin America's fastest-growing pharmaceutical and personal care businesses. The company specializes in the development, marketing, and sale of a diverse portfolio of premium branded products. Many of these products lead their respective markets in terms of sales and market share. Genomma Lab adopts a sound business model, which combines a unique process for new product development with consumer-centric marketing strategies, a widespread retail distribution network, and a highly adaptable, cost-effective supply chain operating model. For further information, you can visit their official website at www.genommalab.com.

Genomma Lab’s shares are traded on the Mexican Stock Exchange under the ticker symbol 'LABB'. As the company continues to refine its financial strategies and build upon its core competencies, there lies a promising outlook for its future engagement in the broader pharmaceutical market.

Looking Forward

In conclusion, Genomma Lab's proactive measures towards refinancing highlight the company's focus on long-term sustainability and strategic expansion. This initiative not only demonstrates financial prudence but also embodies the company's broader vision to enhance the healthcare landscape in Latin America by providing essential products to consumers. With the right financial tools in hand, Genomma Lab is poised for continued growth and success in the competitive pharmaceutical sector.